CTT Pharma, a Canadian developer of drug-delivery technologies is taking Aurora Cannabis to court. CTT claims the marijuana giant is making a bad-faith effort to avoid paying what it owes under a licensing agreement they have. On August 26th, a statement of claim was filed in the Ontario Superior Court of Justice. Aurora Cannabis and its subsidiary CanniMed Therapeutics were listed as the defendants. In early 2017, Ontario-based CTT Pharma entered a 15-year licensing agreement with CanniMed to make and sell sublingual cannabis products using CTT’s patented rapid-onset Oral Dissolvable Thin Film technology. In 2018 Aurora became a sublicensee under the agreement after acquiring CanniMed, and started selling the product in late 2019. A payment of US$40,000 fee upon execution of the agreement was by CanniMed to CTT however CTT says a further payment worth US$935,000 upon Health Canada approval of the products went unpaid, along with the patent maintenance fees worth more than CA$150,000.

Marijuana Business Daily, 09/03/2020 09:45:05

Open article: https://mjbizdaily.com/aurora-cannabis-faces-lawsuit-over-sublingual-strip-licensing-agreement/